Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Reaffirms Buy Rating and Price Target for Mayville Engineering

Elaine Mendonca by Elaine Mendonca
March 7, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On March 7, 2024, analyst Tim Moore from EF Hutton reiterated his positive outlook on Mayville Engineering (NYSE: MEC), maintaining a Buy rating and setting a price target of $22. This reaffirmation underscores Moore’s confidence in the company’s potential for growth and success in the market.

MEC Stock Performance on March 7, 2024: Strong Day Despite After-Hours Drop

On March 7, 2024, MEC stock showed a strong performance, with the price of shares increasing by $0.87, or 6.93%, since the market last closed. The stock closed at $13.42, trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that MEC has been showing stability and strength in its price momentum.

However, in after-hours trading, the stock dropped by $0.69. This could be due to various factors such as profit-taking by investors or market volatility. It is important for investors to keep an eye on after-hours trading activity as it can have an impact on the stock price when the market opens the next day.

Despite the drop in after-hours trading, the overall performance of MEC stock on March 7 was positive, with a significant increase in the price of shares. Investors should continue to monitor the stock’s performance and stay informed about any news or developments that could affect its price in the future.

MEC Stock Performance Analysis: Revenue Up, Net Income Down – March 7, 2024 SEO

On March 7, 2024, MEC stock had a mixed performance based on the latest financial data provided by CNN Money. The company reported a total revenue of $588.42 million for the past year, which represented a 9.09% increase compared to the previous year. However, the total revenue remained flat at $148.58 million for the last quarter.

In terms of net income, MEC reported a net income of $7.84 million for the past year, which was a decrease of 58.11% compared to the previous year. The net income also remained flat at $2.23 million for the last quarter.

Earnings per share (EPS) for MEC stock was reported at $0.38 for the past year, showing a decrease of 58.03% compared to the previous year. However, EPS increased by 55.19% to $0.11 for the last quarter.

Overall, MEC stock showed a mixed performance on March 7, 2024. Investors should closely monitor the company’s financial performance and market trends to make informed decisions regarding MEC stock.

Tags: MEC
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Pharmaceutical Markets and money

Novo Nordisks Amycretin A GameChanger in Weight Loss Treatment

MA stock news

Recent Insider Transactions in Penny Stocks

Finance_Assets

Analyst Insights and Price Targets for Sitio Royalties NYSE STR

Recommended

Baidu Stock

Baidu’s Strategic Moves in Autonomous Driving and AI Draw Mixed Investor Reactions

1 month ago

Windtree Therapeutics Achieves Financial Stability and Advances Clinical Programs

2 years ago
Technology Data analytics Stock Bull Market

Anticipation High for Adobes FirstQuarter Financial Results and AI Innovation

2 years ago
Ideaya Biosciences Stock

Ideaya Biosciences: A Tale of Market Skepticism and Clinical Promise

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

Is Darden Restaurants Facing a Critical Test?

Critical Juncture for USA Rare Earth as Earnings and Chinese Export Curbs Collide

AES Shares Surge on Potential $38 Billion Acquisition Speculation

Kura Oncology Investors Await Crucial FDA Verdict

Cadence Design Stock: A Battle Between Fundamentals and Market Signals

Trending

DuPont de Nemours Stock
Analysis

DuPont Faces Critical Test as Quarterly Results Loom

by Dieter Jaworski
November 6, 2025
0

DuPont de Nemours finds itself at a pivotal moment as the chemical giant prepares to release quarterly...

Sarepta Therapeutics Stock

Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure

November 6, 2025
Emerson Electric Stock

Emerson Electric’s Strategic Pivot Faces Market Scrutiny

November 6, 2025
Lanzatech Global Stock

EU Grant Provides Critical Boost for LanzaTech’s Carbon Recycling Technology

November 6, 2025
Darden Restaurants Stock

Is Darden Restaurants Facing a Critical Test?

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DuPont Faces Critical Test as Quarterly Results Loom
  • Sarepta Therapeutics Shares Plummet Following Critical Clinical Trial Failure
  • Emerson Electric’s Strategic Pivot Faces Market Scrutiny

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com